HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.

Abstract
Triple-negative breast cancer (TNBC) lacking of oestrogen receptor, progesterone receptor, and epidermal growth factor receptor type 2 is a highly malignant disease which results in a poor prognosis and rare treatment options. Despite the use of conventional chemotherapy for TNBC tumours, resistance and short duration responses limit the treatment efficacy. Therefore, a need exists to develop a new chemotherapy for TNBC. The aim of this study was to examine the anti-cancer effects of nafamostat mesilate (NM), a previously known serine protease inhibitor and highly safe drug on breast cancer cells. Here, we showed that NM significantly inhibits proliferation, migration, and invasion in MDA-MB231 cells, induces G2/M phase cell-cycle arrest, and inhibits the expression of cyclin-dependent kinase 1 (CDK1). Exposure of MDA-MB231 cells to NM also resulted in decreased transcription factor activities accompanied by the regulated phosphorylation of signalling molecules and a decrease in metalloproteinases, the principal modulators of the extracellular environment during cancer progression. Especially, inhibition of TGFβ-stimulated Smad2 phosphorylation and subsequent metastasis-related gene expression, and downregulation of ERK activity may be pivotal mechanisms underlying inhibitory effects of NM on NM inhibits lung metastasis of breast cancer cells and growth of colonized tumours in mice. Taken together, our data revealed that NM inhibits cell growth and metastasis of TNBC cells and indicated that NM is a multi-targeted drug that could be an adjunct therapy for TNBC treatment.
AuthorsSunam Mander, Dong-Joo You, Sumi Park, Dong Hwi Kim, Hyo Jeong Yong, Dong-Sik Kim, Curie Ahn, Yun-Hee Kim, Jae Young Seong, Jong-Ik Hwang
JournalArchives of pharmacal research (Arch Pharm Res) Vol. 41 Issue 2 Pg. 229-242 (Feb 2018) ISSN: 1976-3786 [Electronic] Korea (South)
PMID29196918 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Benzamidines
  • Guanidines
  • nafamostat
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Benzamidines
  • Cell Movement (drug effects, physiology)
  • Female
  • Guanidines (pharmacology, therapeutic use)
  • Humans
  • MCF-7 Cells
  • Mice
  • Mice, SCID
  • Triple Negative Breast Neoplasms (drug therapy, pathology)
  • Tumor Burden (drug effects, physiology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: